2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2191

Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
Abstract Number: 2192

User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)
Abstract Number: 2193

Online Direct-to-Patient Recruitment for Systemic Lupus Erythematosus Results in Rapid Enrollment
Abstract Number: 2194

Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China
Abstract Number: 2195

Predictive Factors of a Positive PET/CT Scan for Vascular Involvement in Patients with Polymyalgia Rheumatica
Abstract Number: 2196

Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Abstract Number: 2197

Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database
Abstract Number: 2198

Evaluation of 18F-Fluorodeoxyglucose PET-CT Score at Baseline on the Therapeutic Response to Prednisone in Polymyalgia Rheumatica: A Retrospective Study
Abstract Number: 2199

Active Disease and Follow up 18f-FDG-PET/CT in Patients with Giant Cell Arteritis. Which Treatment Is More Likely to Achieve Remission?
Abstract Number: 2200

Does an 18f-FDG-PET/CT in Patients with Giant Cell Arteritis in Clinical Remission Make Sense?
Abstract Number: 2201

Evaluation of 18f-Fluorodeoxyglucose Positron Emission Tomography/ Magnetic Resonance Imaging (18F-FDG PET/MRI) in C Protein-Induced Myositis Model in Mice
Abstract Number: 2202

The Relationship between Periodontitis and the Treatment Response to Biologics in Rheumatoid Arthritis Patients; A Post-Hoc Analysis Using [18F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
Abstract Number: 2203

Atherosclerotic Inflammation in Rheumatoid Arthritis Patients: A Post-Hoc Study Using Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
Abstract Number: 2204

Clinical Utility of a Multi-Energy Spectral CT in Crystal Arthritis
Abstract Number: 2205

Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Measurement of Dissolution of Urate Deposits Associated with Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin By Dual Energy Computed Tomography

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].